SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-162322
Filing Date
2022-05-27
Accepted
2022-05-27 16:06:10
Documents
13
Period of Report
2022-05-24
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d480537d8k.htm   iXBRL 8-K 54419
2 EX-3.1 d480537dex31.htm EX-3.1 5400
  Complete submission text file 0001193125-22-162322.txt   193184

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20220524.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20220524_lab.xml EX-101.LAB 19504
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20220524_pre.xml EX-101.PRE 12154
7 EXTRACTED XBRL INSTANCE DOCUMENT d480537d8k_htm.xml XML 3678
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 22977368
SIC: 2834 Pharmaceutical Preparations